Nafamostat Mesilate

DRUG9 trials

Conditions

Acute Kidney InjuryCOVID-19COVID19Extracorporeal Membrane Oxygenation ComplicationNafamostat MesilatePharmacokineticsSepsisSepsis-induced Coagulopathy

Phase 1

Oral Nafamostat in Healthy Volunteers (NAF-101)

CompletedNCT04406415

Ensysce BiosciencesPharmacokinetics

Start: 2020-09-21End: 2021-05-14Updated: 2024-09-24

DEFINE - Evaluating Therapies for COVID-19

CompletedNCT04473053

University of EdinburghCOVID-19

Start: 2020-07-03End: 2025-04-30Updated: 2025-08-07

Phase 2

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

NCT04352400

University Hospital PadovaCOVID19

Start: 2021-06-04End: 2024-12-31Target: 256Updated: 2023-11-01

A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

CompletedNCT04623021

Chong Kun Dang PharmaceuticalCOVID-19

Start: 2020-09-25End: 2020-12-12Updated: 2021-02-02

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

CompletedNCT04628143

Chong Kun Dang PharmaceuticalCOVID-19

Start: 2020-12-21End: 2021-04-05Updated: 2021-08-13

Phase 3

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

TerminatedNCT04390594

Institut Pasteur de DakarCOVID-19

Start: 2020-08-13End: 2023-02-08Updated: 2024-06-21

Phase 4

Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

CompletedNCT02478242

Kyungpook National University HospitalAcute Kidney Injury

Start: 2010-07-31End: 2015-06-30Updated: 2015-06-23

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

Not yet recruitingNCT06078839

Xu LiNafamostat Mesilate, Sepsis, Sepsis-induced Coagulopathy

Start: 2023-10-01End: 2026-10-01Target: 778Updated: 2023-10-12

Unknown Phase

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

RecruitingNCT06276010

Xiaotong HouExtracorporeal Membrane Oxygenation Complication

Start: 2024-07-01End: 2026-12-31Target: 80Updated: 2025-09-25

Related Papers

Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial

Trials2025-07-29

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

American Journal of Respiratory and Critical Care Medicine2022-08-1637 citations

Evaluation of new or repurposed treatments for COVID-19: protocol for the phase Ib/IIa DEFINE trial platform

BMJ Open2021-12-016 citations

Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial.

2021-10-2762 citations